

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-11 (canceled):

Claim 12 (withdrawn): A method for the treatment of disorders associated with bone remodeling which comprises administering to a person in need of such treatment the ingestible composition of claim 11.

Claim 13 (withdrawn): The method according to claim 11, wherein the disorder is osteoporosis, Paget's disease of bone, Osteomyelitis, infectious lesions in bone leading to bone loss, hypercalcemia, osteopenia, osteonecrosis, bone loss due to osteoarthritis or rheumatoid arthritis, periodontal bone loss or osteolytic metastasis.

Claim 14 (withdrawn): A method for the treatment or prophylaxis of immune disorders which comprises administering to a person in need of such treatment the ingestible composition of claim 11.

Claim 15 (withdrawn): The method according to claim 14, wherein the immune disorder is allergy, autoimmunity, inflammatory bowel diseases, systemic autoimmune conditions, dysregulation of cell proliferation and apoptosis and immunopathological conditions of the skin, the oral cavity, the gastrointestinal, urogenital or respiratory tracts.

Claim 16 (withdrawn): The method according to claim 14, wherein the disorders are associated with prematurity and/or low birth weight and the composition is administered to a child in need of such treatment.

Claim 17 (currently amended): A food material comprising an osteoprotegerin isolated from human or bovine milk or colostrum, wherein the osteoprotegerin includes a glycosylation pattern giving rise to a polypeptide having a molecular weight of approximately 130 kDa, wherein the osteoprotegerin has been added to the food material and wherein said food material is selected from the group consisting of milk, yogurt, curd, cheese, fermented milks, milk-based fermented products, ice-creams, fermented cereal-based products, milk-based powders, infant formulae and pet food.

Claim 18 (previously presented): A method of making a food material, enteral composition or pharmaceutical composition, the method comprising providing the food material, enteral composition or pharmaceutical composition and adding to the food material, enteral composition or pharmaceutical composition an amount of osteoprotegerin isolated from human or bovine milk or colostrum effective to assist in formation of lymphoid tissues and regulation of immune responses in a subject that consumes the composition, wherein the osteoprotegerin includes a glycosylation pattern giving rise to a polypeptide having a molecular weight of 130 kDa and wherein the food material is selected from the group consisting of milk, yogurt, curd, cheese, fermented milks, milk-based fermented products, ice-creams, fermented cereal-based products, milk-based powders, infant formulae and pet food.

Claim 19 (previously presented): A food material, enteral composition or pharmaceutical composition comprising osteoprotegerin obtained from recombination methods in cells yielding a glycosylation pattern as found in the milk-OPG, wherein the osteoprotegerin includes a glycosylation pattern giving rise to a polypeptide having a molecular weight of 130 kDa.

Claim 20 (previously presented): Osteoprotegerin isolated from human or bovine milk or colostrum, wherein the osteoprotegerin includes a glycosylation pattern giving rise to a polypeptide having a molecular weight of 130 kDa, wherein the osteoprotegerin has a polypeptide sequence identified by SEQ ID NO: 1.

Claims 21-22 (canceled):

Claim 23 (previously presented): An enteral composition or a pharmaceutical composition comprising osteoprotegerin isolated from human or bovine milk or colostrum, wherein the osteoprotegerin includes a glycosylation pattern giving rise to a polypeptide having a molecular weight of 130 kDa and wherein the osteoprotegerin is in an amount effective to assist in formation of lymphoid tissues and regulation of immune responses in a subject that consumes the composition.

Claim 24 (previously presented): The enteral or pharmaceutical composition according to claim 23, which is selected from the group consisting of a solution, dried oral supplement, liquid oral supplement, dry tube-feeding or liquid tube-feeding.

Claim 25 (previously presented): A method of making a food material, enteral composition or pharmaceutical composition, the method comprising providing the food material, enteral composition or pharmaceutical composition and adding to the food material, enteral composition or pharmaceutical composition an amount of osteoprotegerin isolated from human or bovine milk or colostrum effective to assist in formation of lymphoid tissues and regulation of immune responses in a subject that consumes the composition, wherein the osteoprotegerin includes a glycosylation pattern giving rise to a polypeptide having a molecular weight of 130 kDa.

Claim 26 (previously presented): The method according to claim 25, wherein the amount of osteoprotegerin is added to a food material selected from the group consisting of milk, yogurt, curd, cheese, fermented milks, milk-based fermented products, ice-creams, fermented cereal-based products, milk-based powders, infant formulae and pet food.

Claim 27 (previously presented): The method according to claim 25, wherein the amount of osteoprotegerin is added to an enteral or pharmaceutical composition.

Claim 28 (currently amended): An ingestible product made by the method of claim 25, a method of making a food material, enteral composition or pharmaceutical composition, the method comprising providing the food material, enteral composition or pharmaceutical composition and adding to the food material, enteral composition or pharmaceutical composition an amount of osteoprotegerin isolated from human or bovine milk or colostrum effective to assist in formulation of lymphoid tissue and regulation of immune responses in a subject that consumes the composition, wherein the osteoprotegerin includes a glycosylation pattern giving rise to a polypeptide having a molecular weight of 130 kDa.